Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angiotech’sVascular Wrap cuts amputation incidence

This article was originally published in The Gray Sheet

Executive Summary

A single-blind study of 109 patients at nine clinical centers in Europe finds that the control group had about a 19% higher probability of amputation compared with the group treated with Angiotech's Vascular Wrap. The paclitaxel-eluting mesh prevents scar formation that often leads to graft failure in patients with end-stage peripheral arterial disease, according to the firm. Angiotech expects the product to launch late this year in the UK and Germany after it gains a CE mark. FDA designated the combination product as a device in 2005, which could result in a quicker regulatory timeline than if it had been designated a drug, Angiotech says (1"The Gray Sheet" Jan. 2, 2006, p. 4). The firm is enrolling patients in its PREVAIL U.S. pivotal trial to assess the product in end-stage renal patients undergoing hemodialysis...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT024174

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel